CVS HEALTH (CVS) Earnings Date & Reports

Key Takeaways

• CVS Health reported third-quarter 2026 total revenues of $108.4 billion, up 5.4% year over year and above the consensus estimate of roughly $104.7 billion.
• Adjusted earnings per share (EPS, or profit per share excluding one-time items) came in at $2.09, topping the consensus estimate of $1.65, while GAAP diluted EPS (the standard accounting measure) was $1.68.
• The company raised its full-year 2026 guidance across the board, including adjusted EPS to at least $8.20 and operating cash flow to at least $15.5 billion.
• The Health Care Benefits segment, led by Aetna, showed the biggest improvement, with adjusted operating income rising to $912 million from $314 million a year earlier.
• Despite the earnings beat, shares fell sharply after the company confirmed plans to split into two independent public companies by the first half of 2028.
• For more details on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the additional pages linked here.
• Interested in automated market insights? Explore Trending AI Robots to discover data-driven trading strategies.

Earnings Context and Why It Matters

CVS Health's third-quarter report carries outsized weight because the company sits at the intersection of retail pharmacy, pharmacy benefit management, and health insurance through its Aetna business. The prior year's third quarter included a $5.7 billion goodwill impairment charge that pushed results to a loss, so this quarter offered a cleaner read on whether the company's margin-recovery efforts are working. Investors were also watching for signs that elevated medical costs — a persistent headwind across the managed-care industry — are finally moderating. Beyond the numbers, the quarter doubled as a strategic milestone, with management confirming a long-anticipated plan to separate its health care and retail pharmacy businesses into two standalone companies.

Reported Results

For the three months ended September 30, 2026, CVS Health reported total revenues of $108.4 billion, a 5.4% increase from $102.9 billion a year earlier and above the consensus estimate of about $104.7 billion. Adjusted EPS rose to $2.09 from $1.60 in the prior-year period, comfortably exceeding the $1.65 consensus. GAAP diluted EPS was $1.68, a sharp swing from the prior-year loss of $3.13 per share that primarily reflected the absence of the 2025 goodwill impairment charge.

Segment performance was mixed but broadly improved. The Health Care Benefits division, anchored by Aetna, posted revenue of $36.9 billion (up 2.4%) and adjusted operating income of $912 million, up from $314 million, while its medical benefit ratio (MBR — the share of premium dollars spent on medical care) improved to 91.3% from 92.8%. Health Services generated $54.0 billion in revenue (up 9.5%) and adjusted operating income of $2.1 billion. Pharmacy & Consumer Wellness revenue declined 2% to $35.5 billion, though adjusted operating income still grew more than 10%.

On guidance, management raised its full-year 2026 adjusted EPS outlook to at least $8.20 (from $7.90–$8.10), its revenue outlook to at least $420 billion, and its operating cash flow outlook to at least $15.5 billion (up from $11.5 billion).

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Whether you are tracking a specific ticker like CVS or surveying an entire sector, the tool streamlines the research process with data-driven signals.

Market Reaction and Investor Sentiment

Despite beating expectations on both revenue and adjusted earnings and raising full-year guidance, CVS Health shares declined on the day of the report. The negative reaction was driven less by the quarterly numbers than by the confirmation of a corporate breakup: the company plans to split its health care solutions business (including Aetna, CVS Caremark, and Oak Street Health) from its retail pharmacy operations, which will be branded CVS Pharmacy, with completion targeted for the first half of 2028. Investors weighing the execution risk and potential near-term disruption of a separation appeared to overshadow what was otherwise a solid quarter, with the stock trading lower in double-digit percentage terms in intraday trading. The reaction underscores that strategic uncertainty, not just earnings, is now a key driver of sentiment.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will focus on several themes tied directly to this report. First, the announced separation introduces a multi-year execution story. Management expects to complete the split by the first half of 2028, and any updates on timing, capital structure, and leadership transitions will be closely watched.

Second, the margin recovery at Aetna remains the central financial swing factor. The improvement in the medical benefit ratio to 91.3% is encouraging, but management maintained a cautious view given still-elevated medical cost trends. Sustained progress here is essential to the company's upgraded full-year adjusted EPS target of at least $8.20.

Third, the Health Services segment faces a more challenging setup heading into 2027. Management expects adjusted operating income of at least $7 billion next year, describing 2027 as a trough year before growth resumes, partly because of pressures in its 340B drug-pricing business and pharmacy benefit management client attrition.

Finally, the company pointed to 2027 adjusted EPS of at least $8.65, implying roughly 13% growth from the 2026 baseline. How well the company delivers against these targets — while managing a major restructuring — will likely define the next phase of the investment narrative.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations